Marc Iglarz

Summary

Affiliation: Actelion Pharmaceuticals Ltd
Country: Switzerland

Publications

  1. ncbi Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats
    Martine Clozel
    Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    Exp Biol Med (Maywood) 231:967-73. 2006
  2. ncbi Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP
    Qian Pu
    Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    J Hypertens 26:322-33. 2008
  3. ncbi At the heart of tissue: endothelin system and end-organ damage
    Marc Iglarz
    Actelion Pharmaceuticals Limited, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    Clin Sci (Lond) 119:453-63. 2010
  4. ncbi Mechanisms of ET-1-induced endothelial dysfunction
    Marc Iglarz
    Actelion Pharmaceuticals Ltd, CH 4123 Allschwil, Switzerland
    J Cardiovasc Pharmacol 50:621-8. 2007
  5. ncbi Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist
    Marc Iglarz
    Drug Discovery Department, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    J Pharmacol Exp Ther 327:736-45. 2008
  6. ncbi Role of endothelin-1 in hypertension
    Marc Iglarz
    Clinical Research Institute of Montreal, 110 Pine Avenue West, Quebec H2W 1R7, Canada
    Curr Hypertens Rep 5:144-8. 2003
  7. ncbi Endothelin-2 in ovarian follicle rupture
    Chemyong Ko
    Department of Clinical Sciences, University of Kentucky, Lexington, 40536, USA
    Endocrinology 147:1770-9. 2006
  8. ncbi Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesis
    Pierre Beaucage
    Faculte de Pharmacie, Universite de Montreal, Montreal, Quebec, Canada
    J Hypertens 23:329-35. 2005
  9. ncbi Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction
    Farhad Amiri
    Experimental Hypertension, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    Circulation 110:2233-40. 2004
  10. ncbi Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system
    Marc Iglarz
    Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada
    Am J Hypertens 17:597-603. 2004

Collaborators

Detail Information

Publications16

  1. ncbi Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats
    Martine Clozel
    Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    Exp Biol Med (Maywood) 231:967-73. 2006
    ....
  2. ncbi Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP
    Qian Pu
    Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
    J Hypertens 26:322-33. 2008
    ..We evaluated the effects of combining an angiotensin II type 1 (AT1) receptor blocker (ARB, valsartan) and a NEPI (CGS 25354) in comparison with a dual ACEI/NEPI (CGS 30440) in stroke-prone spontaneously hypertensive rats (SHRSP)...
  3. ncbi At the heart of tissue: endothelin system and end-organ damage
    Marc Iglarz
    Actelion Pharmaceuticals Limited, Gewerbestrasse 16, CH 4123 Allschwil, Switzerland
    Clin Sci (Lond) 119:453-63. 2010
    ..The tissue ET system allows therapeutic interventions to provide organ selectivity and beneficial effects in diseases associated with tissue inflammation, hypertrophy or fibrosis...
  4. ncbi Mechanisms of ET-1-induced endothelial dysfunction
    Marc Iglarz
    Actelion Pharmaceuticals Ltd, CH 4123 Allschwil, Switzerland
    J Cardiovasc Pharmacol 50:621-8. 2007
    ....
  5. ncbi Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist
    Marc Iglarz
    Drug Discovery Department, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    J Pharmacol Exp Ther 327:736-45. 2008
    ..This profile makes macitentan a new agent to treat cardiovascular disorders associated with chronic tissue ET system activation...
  6. ncbi Role of endothelin-1 in hypertension
    Marc Iglarz
    Clinical Research Institute of Montreal, 110 Pine Avenue West, Quebec H2W 1R7, Canada
    Curr Hypertens Rep 5:144-8. 2003
    ..Increasing evidence underscores the potential therapeutic benefit of ET receptor antagonists in different hypertension-related complications, not only in essential hypertension, but also in patients with type 2 diabetes...
  7. ncbi Endothelin-2 in ovarian follicle rupture
    Chemyong Ko
    Department of Clinical Sciences, University of Kentucky, Lexington, 40536, USA
    Endocrinology 147:1770-9. 2006
    ..As a target tissue of EDN2 action, we identified a layer of smooth muscle cells in the follicular wall of each follicle. Taken together, our data indicate that EDN2 induces follicular rupture by constricting periovulatory follicles...
  8. ncbi Position of Src tyrosine kinases in the interaction between angiotensin II and endothelin in in vivo vascular protein synthesis
    Pierre Beaucage
    Faculte de Pharmacie, Universite de Montreal, Montreal, Quebec, Canada
    J Hypertens 23:329-35. 2005
    ..Since Src tyrosine kinases can be activated by both agonists, we studied their role in the trophic action of angiotensin II, endothelin and their interaction in rat small mesenteric arteries...
  9. ncbi Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction
    Farhad Amiri
    Experimental Hypertension, Clinical Research Institute of Montreal, Montreal, Quebec, Canada
    Circulation 110:2233-40. 2004
    ..To directly test the role of endothelium-derived ET-1 in cardiovascular pathophysiology, we specifically targeted expression of the human preproET-1 gene to the endothelium by using the Tie-2 promoter in C57BL/6 mice...
  10. ncbi Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiotension system
    Marc Iglarz
    Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada
    Am J Hypertens 17:597-603. 2004
    ..CONCLUSIONS: Our data suggest that the profibrotic but not the hypertrophic action of aldosterone are mediated at least in part by reactive oxygen species generation and involve an interaction with the renin-angiotensin system...
  11. ncbi Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats
    Dierk H Endemann
    CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, Canada
    Hypertension 43:1252-7. 2004
    ..These effects were attenuated by eplerenone, particularly in the salt-loaded state, underlining the pathophysiological role of aldosterone in salt-sensitive hypertension...
  12. ncbi Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension
    Marc Iglarz
    CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada
    Hypertension 42:737-43. 2003
    ..Taken together, these data indicate a modulatory role of PPAR activators on cardiac remodeling in mineralocorticoid-induced hypertension, in part associated with decreased ET-1 production...
  13. ncbi Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice
    Agostino Virdis
    Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada
    Arterioscler Thromb Vasc Biol 23:1352-7. 2003
    ..We evaluated the effect of hyperhomocystinemia and angiotensin (Ang) II on vascular function and structure in methylenetetrahydrofolate reductase knockout mice (Mthfr+/-)...
  14. ncbi Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension
    Marc Iglarz
    CIHR Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montreal, University of Montreal, Montreal, Quebec, Canada
    Arterioscler Thromb Vasc Biol 23:45-51. 2003
    ..CONCLUSIONS: PPAR-alpha and -gamma activators were able to modulate endogenous production of ET-1 and had beneficial vascular effects in endothelin-dependent hypertension...
  15. ncbi Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro
    Marc Iglarz
    , IFR Circulation-Paris VII, , Paris, France
    Hypertension 39:209-13. 2002
    ..These changes in vascular reactivity might help to understand the relations between this polymorphism and cardiovascular disorders...
  16. ncbi Genetic determinants of vascular reactivity
    Daniel Henrion
    INSERM U 541, 41 Bd de la Chapelle, 75475 Paris, Cedex 10, France
    Curr Hypertens Rep 4:41-8. 2002
    ....